STOCK TITAN

Progyny, Inc. SEC Filings

PGNY Nasdaq

Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

When you research Progyny, the first numbers you chase are live-birth success rates, employer contract renewals, and network clinic costs. Those details hide inside dense SEC documents, not glossy press releases. This page gathers every Progyny SEC filing explained simply, so you no longer sift through hundreds of pages to verify margin trends or Smart Cycle utilization rates.

Use our AI-powered summaries to jump directly to what matters: the Progyny annual report 10-K simplified spotlights outcome statistics and revenue per member, while the latest Progyny quarterly earnings report 10-Q filing breaks down reimbursement shifts and new client wins. Sudden contract announcements? The Progyny 8-K material events explained section flags them within minutes of hitting EDGAR. If you’re tracking leadership incentives, our system streams Progyny Form 4 insider transactions real-time, alerting you to every Progyny executive stock transactions Form 4.

Here’s how professionals use the page:

  • Compare quarter-over-quarter embryo transfer success rates with one-click Progyny earnings report filing analysis.
  • Monitor governance changes through the Progyny proxy statement executive compensation link to gauge retention costs.
  • Stay ahead of market moves with instant notifications on Progyny insider trading Form 4 transactions.
Stock Titan’s real-time feed pairs each document with “why-it-matters” notes, making understanding Progyny SEC documents with AI practical. All filings, all in one place—ready when you are.

Rhea-AI Summary

Progyny, Inc. director and Executive Chairman David J. Schlanger reported a sale of 1,893 shares of Progyny common stock on 10/01/2025 at a price of $21.52 per share. After the transaction, the filing shows he beneficially owns 220,419 shares, held directly. The filing states the shares sold were withheld to cover taxes upon the vesting of restricted stock units granted to the reporting person. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Progyny director and Chief Executive Officer Peter Anevski reported an insider transaction dated 10/01/2025. The Form 4 shows 7,977 shares of Progyny common stock were disposed of at a price of $21.52 per share, with the filer retaining beneficial ownership of 539,564 shares following the transaction. The filing explains the sale resulted from shares withheld to cover taxes on vested restricted stock units and notes the remaining reportable shares are held directly by PECO ANEVSKI 2020 SD LLC. The Form 4 was signed by an attorney-in-fact on 10/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Progyny, Inc. (PGNY) insider Allison Swartz, EVP and General Counsel, reported two transactions on 09/04/2025. 339 shares were withheld to satisfy taxes on vested restricted stock units at a per-share value of $23.54, and 599 shares were sold at $23.53 under a Rule 10b5-1 trading plan entered May 13, 2025. The filings show 78,006 shares beneficially owned after the withholding event and 77,407 shares after the sale, reflecting a net reduction in direct holdings. The Form 4 was signed by an attorney-in-fact on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Michael E. Sturmer, President and director of Progyny, Inc. (PGNY), reported a sale of 7,977 shares of common stock on 09/04/2025 at a price of $23.54 per share. After the transaction he beneficially owned 296,658 shares. The filing is coded F(1) and explains the shares were withheld to satisfy tax withholding on vested restricted stock units. The Form 4 was signed by an attorney-in-fact on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Mark S. Livingston, the Chief Financial Officer of Progyny, Inc. (PGNY), reported a routine withholding of shares to cover taxes on vested restricted stock units. On 09/04/2025 he disposed of 479 shares of Progyny common stock at a price of $23.54 per share under transaction code F(1), which the filer explains represents shares withheld to satisfy withholding taxes upon RSU vesting. After the withholding, the reporting person beneficially owned 69,661 shares, held directly. The Form 4 is signed by the reporting person on 09/05/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Form 144 filing for Progyny, Inc. (PGNY) reports a proposed sale of 599 shares of common stock through Fidelity Brokerage Services on 09/04/2025 with an aggregate market value of $14,094.47. The filing shows these shares were acquired the same day as restricted stock vesting and were paid as compensation. The issuer has 85,982,409 shares outstanding. The filing also discloses a prior sale by the same person: 2,398 shares sold on 08/28/2025 for $55,058.08, identified as seller Allison C. Swartz. The form includes the standard signature representation that the seller is not aware of undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Michael E. Sturmer, President and a director of Progyny, Inc. (PGNY), reported a non-discretionary disposition of 448 shares of Progyny common stock on 09/02/2025 at a reported price of $23.67 per share. The filing explains the shares were withheld to satisfy tax withholding obligations arising from the vesting of restricted stock units. After the withholding, Sturmer beneficially owned 304,635 shares, reported in a Form 4 filed by one reporting person and executed via attorney-in-fact on 09/03/2025. The report reflects a routine, tax-related transaction rather than an open-market discretionary sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Mark S. Livingston, Chief Financial Officer of Progyny, Inc. (PGNY), reported a Form 4 disclosing a change in his beneficial ownership. The filing shows that on 09/02/2025 2,032 shares of Progyny common stock were disposed (withheld) at a price of $23.67 per share. The filing explains the shares were withheld to satisfy withholding taxes on vested restricted stock units. After the transaction, the reporting person beneficially owns 70,140 shares (direct ownership). The form was signed by Mr. Livingston on 09/03/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Allison Swartz, EVP and General Counsel of Progyny, Inc. (PGNY), reported two transactions on 08/28/2025. She sold 2,398 shares of Common Stock under a Rule 10b5-1 plan at $22.96 per share and had 1,352 shares withheld to cover taxes on vested restricted stock units at an effective price of $23.02 per share. The filings show total beneficial ownership following these transactions of 78,345 shares. The 10b5-1 plan was entered on May 13, 2025, and the Form 4 was signed via attorney-in-fact on 09/02/2025. The report reflects routine disposition and tax-withholding actions by an officer rather than derivative activity.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Filing
Rhea-AI Summary

Progyny, Inc. (PGNY) filed a Form 144 reporting a proposed sale of 2,398 common shares for an aggregate market value of $55,058.08. The shares are to be sold through Fidelity Brokerage Services on the NASDAQ with an approximate sale date of 08/28/2025. The filing shows 85,982,409 shares outstanding for the class listed.

The securities were acquired on 08/28/2025 through restricted stock vesting and the consideration is listed as compensation. The filer reports no securities sold in the past three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other

FAQ

What is the current stock price of Progyny (PGNY)?

The current stock price of Progyny (PGNY) is $19.5 as of October 23, 2025.

What is the market cap of Progyny (PGNY)?

The market cap of Progyny (PGNY) is approximately 1.7B.
Progyny, Inc.

Nasdaq:PGNY

PGNY Rankings

PGNY Stock Data

1.67B
79.47M
7.58%
103.87%
8.08%
Healthcare Plans
Services-misc Health & Allied Services, Nec
Link
United States
NEW YORK